GSK3A and neoplasm: Tideglusib displayed pharmacokinetic potency in reducing GSK3β-mediated phosphorylation of phospho-β-catenin and consequent increase in total β-catenin in vitro for primary tumor cultures with demonstrated over-expression of GSK3α and GSK3β.